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1Introduction.
Johnny Baird, a 74-year-old-retiree from Arlington, Texas, had his right
cornea accidentally burned during a 1993 ostensibly-routine cataract surgery at
Arlington Memorial Hospital. Today, Baird is nearly blind in his aected eye,
and is also in such pain that he plans to have the eye replaced with a glass one.
In the course of investigating the cause of his mishap, Baird discovered a hospital
incident report, which stated that a disposable laser tip was utilized in his care.
However, one notable detail evident in the hospital's report indicated that the
so-called \disposable" laser tip had not been disposed of after its initial use,
but was instead resterilized and reused in Baird's surgery. Baird's malpractice
suit, which he won in district court and lost on appeal, is now pending before
the Texas Supreme Court.1
Recently, unfortunate tales like Baird's have appeared in the press with in-
creasing frequency and urgency. One familiar story involves a piece of metal
that broke o a catheter and lodged inside the heart of a 32-year-old Kansas
woman early in 1999. The catheter was also labeled disposable; but instead, it
was resterilized and reused six times.2 Reports have also emerged in the media
of two patients blinded in one eye; a premature baby whose foot was burned;
and increased rates of pneumonia in children.3 And even further: accounts of
1Dana Hawkins, \Hospitals' reused tools: reassessing the risk to you," U.S. News & World
Report (November 29, 1999) at 74.
2\FDA exposes patients to risks of medical recycling," USA Today (November 30, 1999)
at 18A.
3\Testimony, February 10, 2000, Robert O'Holla, Vice President of Regulatory Aairs,
Johnson & Johnson, House Commerce Oversight and Investigations, Reuse of Medical De-
2a needle tip that broke o in a patient's jawbone; a guidewire tip that snapped
o in a patient's throat;4 and ve infants who developed lung infections linked
to the reuse of syringes.5
\Blood money." \Dirty medicine." \Risky recycling." These are just a few
of the phrases that the media has used to describe a common occurrence in
many hospitals today: the reuse of medical instruments that have been labeled
\for single-use only."6 Reading these chronicles in the press, one may wonder
why such a seemingly perilous practice continues or has not yet been banned
by appropriate legislation. In truth, however, there are many complex and con-
icting sides to this issue, which has spawned a vigorous debate that currently
involves the highest branches of the federal government, the Food and Drug Ad-
ministration (FDA), hospitals and other health care providers, medical device
manufacturers, and concerned consumer and physicians' groups all around the
nation.
In the interests of curbing health care costs and reducing medical waste, many
clinics and hospitals routinely recycle everything from surgical clamps and for-
ceps to biopsy needles and the tiny angioplasty balloons inserted in heart pa-
tients' arteries to clean out potentially life-threatening blockages. Some com-
mentators estimate that this practice has been going on for over two decades.7
Furthermore, in defense of reuse, health care administrators claim that in this
vices," Federal Document Clearing House Congressional Testimony (February 10, 2000) [here-
inafter O'Holla statement].
4Id.
5\Hospitals reuse medical devices designed for one-time use only," USA Today (November
29, 1999) at 28A.
6John Berlau, \A Ticking Medical Time Bomb?," Investor's Business Daily (September
15, 1999) at A1.
7Id.
3age of skyrocketing health care expenditures, disposing of certain medical in-
struments after only one use simply does not make any sense.
Caught in the middle of this controversy, the FDA has struggled for only the
past few years to devise a conclusive regulatory strategy for medical device reuse.
Many critics claim, however, that this action by the FDA comes too little and
too late. Indeed, one angry journalist has said of the FDA: \Acting more like a
lookout than a law enforcer, the Food and Drug Administration has spent the
past 22 years standing aside as hundreds | perhaps thousands | of hospitals
have begun reusing disposable medical devices, even though such devices have
been bathed in blood, and even though the instruments carry warnings against
the practice."8 Not wishing to rush to judgment like these and other impas-
sioned consumer groups, though, the FDA has chosen to proceed cautiously
thus far, seeking rst to discern and articulate the many discordant views in
this debate before formulating a nal guidance rule.
This paper will explore, in turn, the many dierent perspectives inherent in the
dispute over medical device reuse: the patient and consumer perspective; the
health care provider perspective; the device manufacturer perspective; and also,
the perspective of a new industry player, the third-party medical device repro-
cessor. It will then proceed to review the brief history of FDA regulation of
medical device reuse from its outset to the current day. Finally, it will conclude
with recommendations for additional measures the FDA ought to consider in
arriving at an ultimate regulatory scheme.
8\FDA exposes patients to risks of medical recycling," supra note 2.
4Background.
The practice of reusing medical devices labeled, or otherwise intended, for
only one use (hereinafter referred to as \single-use devices" or SUDs) apparently
began in hospitals in the late 1970s.9 Prior to this time, most medical devices
were considered to be \reusable" (that is, equipment that could be used and re-
processed multiple times). Because most reusable devices were fabricated from
glass, rubber, or metal, early reprocessing of reusable products such as probes
and surgical instruments involved little more than handwiping, dipping, and
soaking in disinfection solutions such as hydrogen peroxide or peracetic acid.10
In the 1970's, Original Equipment Manufacturers (OEMs) began to sell \single-
use" medical devices, as a result of market demand for disposable equipment,
the development of new plastics, and the application of new sterilizing agents
such as ethylene oxide.11 Subsequently, hospitals began to see in the medical
device market products labeled \single-use only" that appeared, in structure
and function, very similar to devices that had formerly been distributed or
continued to be distributed as \reusable." It is believed that the practice of
reprocessing single-use devices expanded when an increasing number of hospi-
tals decided that reuse was a cost-saving measure, and when the amount of
medical waste generated by the use of disposable devices became noticeable.12
The decision to reuse SUDs further led hospitals to begin reprocessing more and
9Center for Devices and Radiological Health (CDRH), \FDA's Proposed Strategy on Reuse




5more complex products (for example, balloon angioplasty catheters and cardiac
catheters), products that required more involved decontamination sterilization
procedures. These procedures might involve wiping the particular device of
visible soil at the point of use, or containing and transporting the device to a
separate decontamination or sterilization work area. As a result, an industry
of third-party reprocessors emerged and evolved in response to the reprocessing
needs of hospitals.
The expansion of this industry of third-party reprocessors, as well as the types of
single-use products that have thus far been subject to reprocessing, has greatly
intensied public concern regarding patient safety, informed consent, and the
ethics of this practice. In addition, many groups have found the issue of equi-
table regulation of OEMs and reprocessing rms to be a particularly troubling
one. An OEM may label a medical device for either multiple use (e.g., an x-ray
machine, a ventilator, or an infusion pump) or for single use (e.g., an implantable
device, an endotracheal tube, or examination gloves). Remarketing industries
now exist for both of these types of devices. These remarketing activities may
consist of reprocessing, refurbishing, rebuilding, servicing, reconditioning, cos-
metically enhancing, or marketing a device \as is" for reuse. In some cases, such
remarketing activities may have the potential to signicantly change a nished
device's performance, safety specications, or intended use. Therefore, many af-
fected consumers have called for FDA to regulate reprocessing rms as strictly
and in the same manner as OEMs.
Statistics
6According to certain studies, about 1 million disposable devices are repro-
cessed every year in the United States.13 At least one in three hospitals na-
tionwide reuses some devices.14 And another survey of 1238 Canadian hospitals
and limited surveys in Britain and the United States have suggested that some
forty percent of institutions reuse medical devices intended for single use.15 The
practice has spawned a $20 million reprocessing industry of loosely-regulated
companies that clean and sterilize equipment for medical facilities.16
The FDA revealed, in an April issue of the Biomedical Market Newsletter, that
464 adverse incidents in the last half of 1999 could possibly have been attributed
to the controversial practice of the reuse of single-use medical devices. The 464
incidents, out of approximately 300,000 reported between August 19 and De-
cember 7, 1999, included roughly 70 dierent product types.17
However, Dr. David Feigal, Director of the FDA Center for Devices & Radio-
logical Health (CDRH), has stated that FDA \can discern no pattern of failures
with reused SUDs that diers from patterns observed with the initial use of
SUDs."18 And according to FDA spokeswoman Sharon Snider, \we have no
13Sylvia Pagan Westphal, \Medical Reuse Rules Proposed: FDA Announces Measures for
Stricter Control on Reprocessing Disposable Hospital Devices," Los Angeles Times (November
2, 1999) at A3.
14Timothy B. Wheeler, \Hospital recycling coming under re; Patients should know of reuse,
senator says," The Baltimore Sun (February 11, 2000) at Business 1C. See also \Testimony,
February 10, 2000, Philip Grossman, House Commerce Oversight and Investigations, Reuse
of Medical Devices," Federal Document Clearing House Congressional Testimony (February
10, 2000) [hereinafter Grossman statement].
15\Reuse of Single-Use Equipment," 268 Lancet 1342 (1985) (Letter to Editor).
16Id.
17\FDA Reveals Over 400 Adverse Incidents Involving Reuse of Medical Devices," Business
Wire (April 3, 2000), Healthwire Section. See also \Testimony, February 10, 2000, David W.
Feigal, Director, Center for Devices and Radiological Health, House Commerce Oversight and
Investigations, Reuse of Medical Devices," Federal Document Clearing House Congressional
Testimony (February 10, 2000) [hereinafter Feigal statement].
18\FDA Reveals Over 400 Adverse Incidents Involving Reuse of Medical Devices," supra
note 17.
7data to indicate people are being injured" by the practice. Says Snider, only
245 of the 300,000 reports of serious device malfunctions received by the agency
in the last total three years could be tied to the reuse of disposable equip-
ment.19
These ambiguous statistical ndings have provided fuel for the arguments of
both sides of the continuing discussion: should hospitals and other health care
providers be allowed to reuse SUDs or not? Let us now examine the perspective
of each stakeholder in this debate for diverging opinions on the subject.
The Patient Perspective: The Dangers of Reprocessing and Reuse.
In the view of patients and other health care consumers, the reprocessing
of single-use medical devices presents a number of potentially signicant health
risks. For the following and other reasons, several foreign health authorities have
banned or disapproved all forms of disposable device reprocessing entirely.20
FDA and Congress are currently debating whether or not they and the U.S.
should follow suit; and patient and consumer groups strongly believe that they
should.
One possible health risk, according to consumers, is that the physical act of
disassembling, cleaning, and manipulating the device during reprocessing may
19Wheeler, supra note 14,
20See, e.g., Commonwealth of Australia, Dep't of Human Services & Health, Draft State-
ment of Commonwealth Policy on the Reuse of Single-Use Therapeutic Devices (May 30,
1994). In addition, several European countries, including Italy and Spain, have prohibited
reuse of single-use devices, and a number of other countries, including England and France,
have issued statements disapproving reuse of disposable products. See Canadian Hospital
Association, Report on the Reuse of Single-Use Medical Devices tbl.3 (1995) (discussing in-
ternational perspectives).
8adversely aect the device's safety or eectiveness. Also, inappropriate ster-
ilization methods may damage device components or materials. For example,
certain devices that incorporate exible plastics may crack or otherwise be dam-
aged under the heat and pressure of steam sterilization.21 Similarly, chemical
germicides used in cleaning may cause surface cracking or \pitting," which may
decrease the mechanical integrity of a device and make it more dicult to con-
taminate and clean before a later use.22 Illustrating these principles, in one
particular case of reprocessed hemodialyzers, for example, the use of overdi-
luted chemical sterilization agents has been blamed for outbreaks of bacterial
and viral infections.23
Conversely, excessively concentrated cleaning agents and inadequate ushing
also may have serious health eects. For example, some reprocessors use formalde-
hyde, a known carcinogen, for disinfection. Formaldehyde residues may remain
in the reprocessed device, which may be infused into patients' bloodstreams.24
Moreover, to ensure the safety and eectiveness of reprocessed devices, it is
also vitally important, in patients' view, to determine the maximum number
of reprocessing cycles. For this purpose, devices designed specically for reuse
21\ENT Endoscopic Sheath Barrier Claims Should Be Based on 30nm or Smaller Virus Size,
FDA Says," F-D-C- Rep. (\The Gray Sheet"), Nov. 11, 1996, at I&W6.
22Food and Drug Administration (FDA), \Guidance on the Content and Format of Pre-
market Notication [510(k)] Submissions for Liquid Chemical Germicides" (Apr. 26, 1995) at
<http://www.fda.gov/cdrh/ode/germic4.html>.
23An outbreak caused the deaths of fteen patients treated at one dialysis center. See Janice
M. Hogan and Thomas E. Colonna, \Products Liability Implications of Reprocessing and
Reuse of Single-Use Medical Devices," 53 Food and Drug Law Journal 387 (1998). Insucient
disinfection of reprocessed hemodialysis equipment also has been linked to transmission of the
HIV virus in several foreign countries. See, e.g., \HIV Transmission in a Dialysis Center |
Colombia (1991-1993)," 274 JAMA 372 (1995); and M. Velandia Scott et al., \Transmission
of HIV in Dialysis Centre," 345 Lancet 1417 (1995).
24In addition, reprocessing workers may experience serious adverse eects from exposure to
formaldehyde vapors where environmental conditions are inadequately controlled. See Hogan
& Colonna, supra note 23, at 387.
9incorporate mechanisms that signal to reprocessors the point at which devices
should be discarded due to deterioration, rather than reprocessed for further
reuse.25 However, medical devices intended for single use incorporate no such
signaling mechanisms.26 Therefore, patients and other consumer groups argue
that reprocessors have no guidance regarding how many additional times a la-
beled \single-use" device may be reused.
FDA's own research has uncovered problems with some reused disposable de-
vices, such as angioplasty balloons that get stretched out of shape through the
cleaning.27 And many concerned consumers believe that the practice of reuse
is entirely too common and overlooked at many hospitals and clinics. As one
reader of The New York Times noted in a letter to the editor:
The reuse of medical devices is of great concern to kidney
dialysis patients, who often have no choice but to accept
what is oered or not receive this lifesaving treatment. Should
an accident occur in a dialysis unit and a patient becomes very
sick or even dies, the rst procedure is to stop reuse of the
dialysis lters until the problem is investigated. This oers
a clue about the dangers of reuse.28
Joel Schoenfeld, CEO of UNIVEC Inc., a maker of auto-disposable syringes,
has also asserted that only syringes that cannot be reused should be available.
\The United States must declare war | war against disease," he said.29 A
25See FDA, \Labeling Reusable Medical Devices for Reprocessing in Health Care Facilities:
Draft Reviewer Guidance" (April 1996).
26FDA has noted the impact of device design on successful reuse and reprocessing. For
example, the agency has stated that, \[a]s a rule, a reusable device should be designed so
that it can be adequately cleaned. If a device cannot be adequately cleaned, any subsequent
disinfection or sterilization process may not achieve the desired result." Id.
27\Hospital Recycling Scrutinized," Dayton Daily News (February 11, 2000) at 15A.
28Gerald H. Dessner, \`Single Use Medical Devices Are Often Used Several Times," The
New York Times (November 13, 1999) at A14.
29Cheryl A. McMullen, \FDA studies instrument reuse," Waste News (February 21, 2000)
at 3.
10vaccine administered in a reused syringe does more harm than good, according
to Schoenfeld.30
Recent Attempts at Patient Legislation
One powerful Maryland state senator believes that recycling SUDs may be
too risky for the operating room. Senator Thomas L. Bromwell, a Baltimore
County democrat and chairman of the Maryland state Finance Committee, has
taken aim at this practice by introducing a bill this past February that would
forbid hospitals and clinics in Maryland from reusing single-use devices unless
they rst notify patients and get their signed consent. Failure to do so could
yield a ne of up to $10,000 per violation.31 \These devices are labeled for one-
time use only for a very good reason," Bromwell said in a statement prepared
for a February hearing on the bill in Annapolis. \That reason is that there is
no scientic proof they can be sterilized and reused safely."32
In California, Assemblyman Thomas Calderon (D-Montebello) also announced,
in August 1999, the introduction of a bill to ban, for a proposed period of two
years, the use of reprocessed devices in the state.33 And U.S. Senator Richard
Durbin (D-Illinois) has also begun to instigate FDA action at the federal level,
recently pushing through an amendment to an appropriations bill that will pro-
vide $1 million for the FDA to begin providing more oversight of the reuse of
30Id.
31Wheeler, supra note 14.
32Id.
33Westphal, supra note 13.
11single-use medical devices.34 According to his spokeswoman Melissa Merz, FDA
needs to ensure \that reprocessed devices be as safe as new devices.... The fact
remains that Congress needs to go further to ensure patients are informed before
a recycled device is used on them."35
Most recently, Representative Anna G. Eshoo (D-California) and Representative
Fred Upton (R-Michigan) introduced legislation that would limit the practice of
reprocessing and reusing medical instruments.36 \It's a dangerous practice that
borders on fraud," said Eshoo.37 The proposed Eshoo-Upton legislation would
require pre-market approval measuring safety and eectiveness for any medical
device intended for reuse. It would also require hospitals to obtain a patient's
informed consent before any recycled item is used in the patient's care. The leg-
islation would further require hospitals and reprocessing companies to monitor
and report any injuries or infections that occur as a result of reusing medical
devices.38 Hearings on the bill were conducted by the House of Representatives
Subcommittee on Oversight and Investigations in February of this year.
Further Views
Many ethics commentators agree with these and other legislators' reasoning
in support of a ban on or stricter regulation of medical device reuse. One skeptic
of medical device reuse, Dr. John H. Fielder, testied before the House Subcom-
34The $1 million is earmarked for the scal year 2000 agriculture spending bill. See Cheryl A.
McMullen, \FDA Readies Regulations for Medical Device Reuse," Crain's Cleveland Business
(September 13, 1999) at 18.
35Westphal, supra note 13.
36H.R. 3148, entitled Reprocessed Single Use Medical Device Patient Safety Act of 1999).
37Anna Eshoo, \Eshoo and Upton Intro Bill to Stop Reuse of Disposable," Congressional
Press Release (October 27, 1999).
38Id.
12mittee in February, saying: \The patient is the ethical center of health care. All
who participate in patient care, directly or indirectly, are ethically obligated to
provide adequate and appropriate care to patients and to safeguard their right
to make informed health care decisions."39 Dr. Fielder, in his testimony, noted
that studies of reprocessed single-use devices by FDA and others have shown
that some devices have debris left in them and are contaminated with fungi,
bacteria, or viruses. Reprocessed devices, therefore, can transmit diseases or
may fail and injure patients.40 He further noted that although there are only a
few reports in the literature of patients being harmed by failure of these devices,
it is likely that device failures are underreported, and also, that physicians may
not always recognize problems caused by reprocessing.41 Dr. Fielder concluded
his testimony by stating that it is \ethically unacceptable" to put people \at
risk" without their informed consent.42 Dr. Fielder expressed skepticism of the
health care savings that hospitals claim would be passed on to patients as a
result of SUD reuse, for several reasons. First, it is not guaranteed that any
savings would directly aect the patients taking the risk, since savings may well
be applied to other hospital service areas. Also, he argued, if these are patients'
benets, no matter how remote, patients should have the right to decide where
they should be spent.43
According to another troubled physician who testied before the House Subcom-
39\Testimony, February 10, 2000, Dr. John H. Fielder, Professor, Philosophy, Ethics Con-
sultant, House Commerce Oversight and Investigations, Reuse of Medical Devices," Federal






13mittee, the most signicant problem FDA and the government faces involves the
reuse of \medical devices that were designed, manufactured, tested, packaged,
and labeled for the sole purpose of a single use in a single patient."44 Says he,
\These are devices for which the very approval from the FDA is contingent upon
information submitted, including the fact that these devices are to be disposed
of after a single use."45 This physician, Dr. Grossman, a gastroenterologist in
Miami who is also a consultant to a device manufacturers' group, also argued
that single-use devices have a number of common design features that make
cleaning or reprocessing dicult or impossible: they tend to be very small and
intricate; they typically have complex wiring systems, such as diagnostic wiring
that carries an electronic signal for measurement; and because many of these
devices are used for the purpose of removing pieces of tissue or altering tissue
during a procedure, they typically have sharp points and harp edges, which
preclude access to its \nooks and crannies," encouraging human debris to get
caught in tightly woven wires or sharp points.46
FDA requires manufacturers to conduct additional testing for devices that are
intended to be reusable, Grossman argues. They must meet FDA criteria to
validate that a device can be cleaned and resterilized multiple times. Data sup-
porting reuse must be submitted to the FDA through the premarket notication
process, whereas FDA is not enforcing these same regulations against reproces-
sors of used single use devices.
Opponents of SUD reprocessing state that public awareness is as yet insucient
44Grossman statement, supra note 14.
45Id.
46Id.
14on this issue. Dr. Grossman, in his February testimony, pointed to a study or-
ganized in October 1997 called \The Medical Device Reuse Awareness Study,"
conducted for Halsted Communications, that supposedly illustrates public re-
sponse as people become aware of medical device reuse.47 In response to the
question posed to 501 participants from Los Angeles, New York, Chicago, and
Atlanta, \How would you feel if a device that by law was designed to be used
once, was reused on you or on someone you love?," people responded as follows:
84% stated that they would be angry; 76% would demand an explanation; 69%
would be frightened; and 59% would ask for a guarantee that the person that
the device was used on before was healthy.48 Also, recently in Japan, a clinic
initiated a policy in which patients were told that there were two kinds of acces-
sories they could use in a procedure: single-use or reprocessed. If they chose the
single-use device, however, they would have to pay an out-of-pocket premium.
Everyone chose to pay the premium.49 According to Dr. Grossman and other
patient advocates, this evidence clearly indicates the strong patient view against
any reuse of medical devices in the health care eld.
The Hospital Perspective: Ecient Patient Care and Business Ne-
cessity.
As noted above, the reprocessing of certain medical devices labeled for single-
use has taken place for over two decades. The American Hospital Association
(AHA) has called reprocessing \a safe and standard medical practice" that hos-
47Id.
48Id. 19% of the respondents from Los Angeles also stated that they would sue if they found
out what happened.
49Id.
15pitals have used \for years with excellent success."50 The American College of
Cardiology has also written to Congress that \there are cardiovascular special-
ists who have been using reprocessed catheters in their labs for more than 20
years and cannot cite a single instance where a reprocessed catheter has broken
or caused infection."51 And the Mayo Clinic has stated that \for more than 20
years, the catheters used in electrophysiology procedures have been reprocessed
at Mayo and have continued to function normally without any evidence of in-
fection."52
Hospitals, according to one reprocessor, originally began to reprocess for two rea-
sons: First, certain devices initially labeled \reusable" were switched to \single-
use" without any structural change in the device. Second, doctors and nurses
recognized the inherent waste in discarding certain devices after one use.53 Ac-
cording to one medical device reprocessor, hospitals nowadays are also fully
aware that the \single-use" label on a medical device does not necessarily mean
that it should be discarded after one use. According to the AHA, \In our view,
the real issue is not whether reuse is appropriate, but whether the single-use
label is a complete and accurate representation of the device."54 For many hos-
pitals, the single-use label is not an accurate representation.
The American Hospital Association has supported reprocessing and is in favor
50\Testimony, February 10, 2000, Mr. Vern Feltner, President, Alliance Medical Corpo-
ration, House Commerce Oversight and Investigations, Reuse of Medical Devices," Federal






16of appropriate FDA regulation of the practice, rather than an outright ban.55
Other spokesmen for hospitals and for companies that reprocess medical devices
say that there is no evidence that patients are subjected to any risk from the
practice of reprocessing.56 These spokesmen believe that state measures such as
the one that Senator Bromwell has proposed for Maryland are \an unnecessary
overreaction" to national news reports such as those of recycled heart catheters
breaking o after being inserted in patients.57
The International Association of Healthcare Central Service Material Manage-
ment has also commented in favor of appropriate FDA regulation, rather than
a ban on SUD reprocessing. The association, which includes 8,500 health care
professionals responsible for the decontamination, sterilization and organization
of medical devices, considers the reprocessing of single-use devices to be a se-
rious patient safety issue. \Our position has been that we don't recommend
reprocessing in health care facilities. If a facility must reprocess to reduce ex-
penses, we recommend they go to a third-party reprocessor that is registered
with FDA, who meets the criteria of the [facility's] health care reuse commit-
tee," association spokeswoman Anne Coell has said.58
According to FDA medical device chief Dr. David Feigal, even unopened, brand-
new, never-before-used heart catheters can break the rst time they are used.
Also, many medical devices are made to be used over and over | yet they,
too, commonly cause infections whenever hospitals do not properly resterilize
55McMullen, supra note 29.
56Wheeler, supra note 14.
57Id.
58Cheryl A. McMullen, \FDA debates device reuse," Waste News (December 20, 1999) at
4.
17them.59 The American Society for Gastrointestinal Endoscopy, a physi-
cians group, has stated: \There is an extensive body of research demonstrating
that many devices labeled as `single use' can be reused after proper cleaning
and restoration, with no risk to patients.... The only beneciary of such dis-
posal is the manufacturer of the items."60 Other doctors' groups, including the
American College of Cardiology, have expressed similar support for reprocessing.
Furthermore, a physician with the Centers for Disease Control and Prevention
recently stated that he \would be just absolutely amazed if [reprocessing] is a
major health problem and [the leading hospitals] have failed to realize it."61
Four recent clinical studies, all published in peer-reviewed scientic medical
journals, have evaluated the safety of reusing heart catheters for certain elec-
trophysiology studies. All of these studies found no evidence that the steril-
ity of reprocessed catheters is a concern or that the incidence of infection is
increased.62 One study published in the medical journal Pacing and Clinical
Electrophysiology in 1988, concluded that the catheters were suciently durable
to be reused well in excess of ve times, and that one-time use of such catheters
appeared to be a medically unnecessary and expensive policy to adopt.63
Economic Arguments
In recent years, the economic issues of patient care have heightened con-
59\Hospital Recycling Scrutinized," Dayton Daily News (February 11, 2000) at 15A.
60Pam Furman, \These devices are safe," USA Today (November 29, 1999) at 28A.
61Id.
62\Prepared Statement of Bruce Lindsay, M.D., F.A.C.C., Associate Professor of Medicine,
Director, Clinical EP Laboratory, Washington University School of Medicine, St. Louis, Mis-
souri, On Behalf of the American College of Cardiology North American Society of Pacing
and Electrophysiology, Before the House Commerce Committee Oversight and Investigations
Subcommittee," Federal News Service (February 10, 2000) [hereinafter Lindsay statement].
63Id.
18cerns among health care providers and others. Some providers may believe that
if disposable medical devices save money, reusing disposable devices will save
even more money. Because single-use medical devices can be so expensive,64
the cost-eectiveness of reuse might seem obvious.65
Richard P. Kidwell, managing attorney for claims and litigation for the Johns
Hopkins Health System, asserts that all device reuse is subject to strict internal
review for safety.66 Hopkins Health System reuses certain catheters in its cardio-
vascular diagnostic laboratory, as well as laser tips in its Wilmer Eye Institute.
Recycling such devices saves about $2,000 per procedure, Kidwell estimates,
which Hopkins passes on to patients and their insurance companies.67
Business arguments for the reuse of single-use medical devices center around
the need for backup supply systems in the face of device delivery problems;
reduced inventory costs and space; and reduced biohazard waste disposal costs.
Critics of SUD reuse note that related costs for reprocessing, quality manage-
ment, liability insurance, and possible lawsuits68 make the cost savings of reuse
uncertain, however.
But Dr. Bruce Lindsay, a cardiologist and member of both the American College
of Cardiology (ACC) and the North American Society of Pacing and Electro-
64For example, cardiac catheters, exclusive of sophisticated angioplasty devices, cost $15 to
$80 each. See M.H. Radany et al., \Is It Safe to Reuse Disposables?", 87 Am. J. Nursing 36
(1987).
65Id. at 35-38; see also \Cardiac Catheter Reuse Targeted by FDA," F-D-C Rep. (\The
Gray Sheet"), July 7, 1997, at I&W2.
66Wheeler, supra note 14.
67Id.
68A survey of 501 consumers, conducted for Halsted Communications by Wilson & As-
sociates, found that 19% of respondents stated that they would sue if they discovered that
disposable medical devices had been reused in their medical treatment without their informed
consent. \Disposable Device Reuse is Opposed by Most Consumers, F-D-C- Rep. (\The Gray
Sheet"), Dec. 22, 1997, at I&W12.
19physiology (NASPE), has come out in favor of the economic benets of medical
device reuse. Dr. Lindsay directs the cardiac electrophysiology laboratory at
Washington University in St. Louis, where more than 1,500 diagnostic and
therapeutic procedures are performed each year. In his 15 years of experience
in the eld of clinical electrophysiology (EP), Dr. Lindsay has stated that he
has never encountered a complication related to the reuse of an EP catheter.69
Dr. Lindsay has further noted that the cost of catheters used to perform elec-
trophysiology studies may range from $100 to as much as $3,000. Dr. Lindsay
also testied before the House Subcommittee in February, and stated then that
experience over the past 30 years has indicated that catheters are quite durable
and can be sterilized for reuse, as has been the practice for many surgical in-
struments.70
Physicians' motive to reuse EP catheters has arisen from their experience that
the catheters are durable and can be safely used for several procedures without
posing an increased risk to the patient. As such, says Dr. Lindsay, it would
be a waste to discard the catheters after a single use.71 The cost savings real-
ized by hospitals that reuse catheters, however, can be substantial, depending
on the volume of procedures and whether catheters are reprocessed internally
or through a commercial reprocessing company. According to Dr. Lindsay, it
is possible for hospitals to reduce their catheter costs by about 35% through
reuse; and at large medical centers these measures may lead to cost savings in
69Lindsay statement, supra note 62.
70Id.
71Id.
20the range of $250,000 to $400,000.72
Since, according to Dr. Lindsay, cardiovascular specialists have been safely us-
ing reprocessed EP catheters to treat their patients for more than 20 years,
he urged that the practice has been proven safe, eective, and cost ecient.
Lindsay stated that Congressional legislation to ban the practice, such as those
introduced by Senator Richard Durbin73 and Representative Anna Eshoo74 is
unwarranted, and that Congress should \defer to the FDA as it perfects a reg-
ulatory strategy for the reuse of medical devices that is based on science and
emphasizes public safety as the rst priority."75
Some physicians, like Dr. James T. Frakes, a gastroenterologist in Rockford,
Illinois, say they do not reuse devices because of liability concerns.76 But Dr.
Frakes also says that such caution comes at a cost. \We cannot aord to use
some single-use accessories in our unit," he said. Indeed, according to Dr. David
E. Haines of the University of Virginia Health System, where electrocardiologists
routinely reuse devices that can cost $1,000 or more per patient (but far less
if they are reused), if patients began to insist that the hospital use brand-new
devices and equipment, \fresh out of the package," for every procedure, \we
would probably decline to take their cases and refer them elsewhere."77 This
result would surely make patient consumers suer as well, and would this cost




75Lindsay statement, supra note 62.
76Gina Kolata, \`Single Use' Medical Devices Are Often Used Several Times," The New
York Times (November 10, 1999) at A1.
77Id.
21Informed Consent
Regarding the issue of informed consent, such as that raised in Senator Bromwell's
proposed Maryland bill, Dr. C. Grin Trotter of the Center for Health Care at
St. Louis University testied before the House Subcommittee in February that
\if standards for reprocessing medical devices are suciently rigorous to ensure
that these devices may be used safely, then there is no moral requirement for
informed consent."78 He noted before the House that the likely risks pertaining
to the use of a reprocessed single-use medical device vary, depending on the
nature of the device, the previous use of the device, the reprocessing method
and the proposed manner in which the device will be reused. These variations
make it dicult to articulate a uniform requirement for informed consent.79
Dr. Trotter noted that if it is determined that the risks of using reprocessed
medical devices are minimal, then the process of trying to disclose these risks to
patients could actually hinder the integrity of informed consent by promoting
irrational concerns (thus constraining understanding and voluntariness). This
would occur because of two pitfalls. First, patients generally do not reason
statistically.80 Also, patients often maintain un-warranted superstitions about
the hazards of contact with others' bodies, similar to how concern about the
transmission of AIDS is sometimes overwrought.81
Dr. Trotter suspects that \it will not be possible to articulate and legislate
78\Prepared Statement of Dr. C. Grin Trotter, Center for Health Care, Saint Louis Uni-
versity, Before the House Commerce Committee Oversight and Investigations Subcommittee,
Subject - Ethical Issues in the Reuse of Single-Use Medical Devices," Federal News Service
(February 10, 2000) [hereinafter Trotter statement].
79Id.
80For example, even when a risk is statistically very remote, most patients will assume that
if it is mentioned, then it is a clinically signicant risk. See Trotter statement, supra note 78.
81Id.
22a uniform standard for obtaining informed consent for the use of reprocessed
SUDs that is more eective or useful than general legal standards that already
pertain in clinical medicine."82 A more promising avenue, he suggests, would
be to rely on the enforcement of eective safety regulations, which would render
informed consent into \a moot issue."83 Dr. Trotter's opinions are representa-
tive of the views of many doctors on the issue of informed consent and how it
relates to medical device reuse, a practice which a majority of physicians believe
should continue to be allowed in hospitals without signicant restriction.
The OEM Perspective: Mixed Motives?
Original manufacturers of medical devices have continually maintained that
hospitals that reuse medical devices are putting patients at grave risk to save
money. \The real issue is patient safety," said Josephine Torrente, president
of the Association of Disposable Device Manufacturers. \Until you prove oth-
erwise, these devices are safe and eective for one use. After that, they're
garbage."84
Robert O'Holla, Vice President of Regulatory Aairs for the Medical Devices &
Diagnostics Group at Johnson & Johnson, also testied before the House Sub-
committee on Oversight and Investigations in February. As Chairman of the
Association of Disposable Device Manufacturers, a trade association of single-
use medical device manufacturers, he claimed that it was \unacceptable to clean
and reuse a delicate, complex medical device that was designed for use in a sin-
82Id.
83Id.
84Fred Charatan, \Controversy erupts over reuse of `single use' medical devices," The West-
ern Journal of Medicine, Vol. 172, No. 1 (January 1, 2000) at 58.
23gle patient and approved by FDA for only one use."85 O'Holla also expressed
his concern regarding the \apparent disinterest" on the part of FDA to the
health and safety of patients.86 O'Holla called for the FDA to apply all of the
provisions of the federal Food, Drug and Cosmetic Act (FDCA or FDC Act)
to reprocessed devices. According to him, \No evidence of harm is needed be-
fore FDA can and should apply the law. The FDC Act and its implementing
regulations establish a presumption that all medical devices are unsafe, and re-
quire that the safety and eectiveness of new or substantially modied devices
be armatively demonstrated prior to their introduction into interstate com-
merce."87 O'Holla argued that claiming that a single use device may be reused
causes the device to be treated as a new device under FDA's regulatory scheme.
O'Holla, in his testimony, cited seven studies of reprocessed biopsy forceps,
which indicated that a lack of sterility assurance was reported in over 45% of
the samples tested.88 Additionally, approximately 75% of the overall 900 sam-
ples of reprocessed devices in the studies failed, either due to the presence of
blood and/or proteinacious matter, bacterial contamination, non-functionality,
or defective packaging.89 O'Holla claimed that the studies also found devices
with mismatched parts, a scalpel blade designed to be blunt that was, instead,
sharpened, a surgical stapler contaminated by a large piece of proteinacious
matter, and devices lacking warnings about latex content.90




89Id. See also Deborah Circelli, \Medical Recycling: Vanguard Medical Concepts Inc.
is part of a growing industry that reprocesses single-use medical equipment and sells it to
hospitals," The Ledger (December 12, 1999) at E1.
90O'Holla statement, supra note 3.
24O'Holla and other OEM manufacturers have particularly decried FDA's lack of
a premarket approval scheme for reprocessed SUDs. O'Holla cited the Medical
Device Amendments of 1976 (MDA), which Congress enacted \for the purpose
of implementing pre-market review of devices because Congress was concerned
that post-marketing regulation of medical devices was inadequate to protect the
public health... there is no justication for a patient to receive less protection
from FDA merely because the device used for the patient's treatment is a repro-
cessed single use device rather than an FDA-cleared reusable device."91 O'Holla
further argued that FDA is violating its Congressional mandate by, in eect,
creating a de facto exemption from the premarket review requirements for most
reprocessed SUDs. \FDA is eecting a double standard that lowers the burden
for reprocessors as compared to OEMs. The protection of U.S. patients requires
that FDA regulate all manufacturers in the same manner, regardless of whether
those manufacturers are deemed OEMs or reprocessors."92 O'Holla concluded
his testimony by calling for FDA quickly to establish timelines for enforcement
of the 510(k) and PMA requirements on all reprocessed SUDs.
Many other medical device manufacturers have complained that they are re-
quired to demonstrate to FDA that their products are safe and eective for
their intended use before they market them to the public. They argue that re-
processing companies that take their single-use devices and attempt to clean and
sterilize them for further use on dierent patients are not required to prove sci-
entically that the devices are still safe and eective, and that this constitutes
91Id.
92Id.
25inequitable regulatory treatment with regard to OEMs. Some manufacturers
believe that by speaking out against medical device reprocessing, they are only
asking that the FDA \safeguard patients by closing this regulatory gap."93
OEMs have further argued that they should not be responsible for providing the
data to the FDA on the safety of reusing SUDs,. Those who have the data, they
say | \the hospitals and companies that conduct and perpetuate this practice"
| should provide the necessary statistics.94 However, these entities, they claim,
\are resisting the eorts of the FDA and Congress to collect and analyze the
data," through tactics such as \cast[ing] aspersions on the motives of the orig-
inal manufacturers of the devices in question."95 In response to hospital
administrators and device reprocessors who claim that OEMs have only come
out against device reprocessing for their own economic motives, one member of
the medical device community wrote:
Instead of trying to drive companies that \reprocess" used
disposable medical devices out of business, we in the medical
device community are trying to ensure that hospitals and
companies that reprocess our single-use devices are held to the
same regulatory standards as we are. We're also trying to
ensure that patients aren't injured or infected by the improper
use of our products.96
To be sure, OEMs have strongly expressed their concern for patient safety
and a belief that medical device reprocessing ought to be regulated in the same
manner as original device manufacturing. Now we turn to the last stakeholder




96\Medical device reuse needs tough scrutiny," Chicago Sun-Times (February 25, 2000) at
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26The Reprocessor Perspective: Providing a Service to the Medical
Community.
The fast-growing medical device reprocessing industry has maintained that
SUD reprocessing and reuse is a safe and eective practice, and that it enables
hospitals and other health care providers to contain what might otherwise be
spiraling health care costs. Reprocessors have argued that OEMs are so con-
cerned with the reprocessing issue simply because they wish to maximize their
own revenues. \The battle is over economics, not safety," contends one repro-
cessing industry lobbyist who opposes Bromwell's Maryland measure.97 In an
attempt to boost sales, goes the argument, manufacturers arbitrarily label many
medical devices for one-time use, even though they had been routinely reused
in the past.
Medical administrators and reprocessors argue that the \single-use" designa-
tion is a choice made by manufacturers, and is not an FDA requirement.98
The Washington-based Association of Medical Device Reprocessors (AMDR)
believes that for many devices, the single-use designation is a marketing deci-
sion, not a safety decision.99 According to the AMDR, \the math is easy | the
more devices that are reprocessed, the fewer brand-new devices are purchased,
and that much less money is made by manufacturers."100
AMDR has presented evidence before the House that manufacturers often des-
ignate devices as single-use for economic reasons, rather than out of a concern
97Wheeler, supra note 14.
98Lindsay statement, supra note 62.
99Feltner statement, supra note 50.
100Id.
27for patient safety. Moreover, a December 11, 1998 episode of NBC's \Dateline"
exposed Johnson & Johnson's practice of labeling as \single-use" contact lenses
that were virtually identical to the lenses that the company had been market-
ing as reusable.101 When asked why it had designated the lenses as single-use,
Johnson & Johnson stated: \If we had changed the label and marketed for gen-
eral use, then we couldn't advertise and create this single-use, daily disposable
category. We made that decision because we felt it was a good business decision
to do it that way."102 Another example involves a letter written by USCI Car-
diology & Radiology Products (USCI) to a hospital explaining that, although
USCI had decided to change the label on a particular device from reusable to
single-use, it had made no structural changes to the device. Specically, USCI
stated: \Our manufacturing processes of Woven Dacron Intracardiac Electrodes
have not changed. These electrodes are made with the same materials and in
the same manner they have been in the past."103 In light of this evidence, man-
ufacturers' protestations that the single-use designation on a device is never
arbitrary, and that \economics must be subordinate to this concern for proper
health" ring hollow for many medical device reprocessors.104
Charles Masek, president of Vanguard Medical Concepts, has said that his com-
pany has safely reprocessed more than 2.5 million devices | ranging from coro-
nary angioplasty balloon catheters and orthopedic blades, burrs, and bits, to
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28founding member of AMDR. Mark Salomon, senior vice president of corporate
development for Vanguard, has stated that current rising health care costs have
caused an even greater need for reprocessing today. Hospitals can save about
half the cost of a new device by reprocessing.106 In addition, the reprocessing
industry promotes competition with the OEMs. Salomon said that three years
ago, single-use GI biopsy forceps sold for $60 each, but manufacturers lowered
the price to $30 because of competition from reprocessors. Vanguard reprocess
the equipment for $15 each. Also, angioplasty balloon catheters sold for about
$800 three years ago, but now the price has dropped to $350. Vanguard repro-
cesses them for $175.107 Vanguard currently reprocesses 13 dierent types of
devices, which Masek said is a narrow spectrum of the hundreds of thousands
of medical devices in the health care market.108
Vern Feltner, President of Alliance Medical Corporation, testied before the
House Subcommittee in February 2000, on behalf of AMDR. In his testimony,
Feltner claimed that the AMDR did not seek exemption from regulation and
oversight.109 To the contrary, Feltner stated that AMDR and the reprocessing
industry could only survive in a \clear, rational regulatory scheme."110 Feltner
cautioned, however, that any regulatory scheme ought to be \based on demon-
strated public safety risks and not on hypothetical risks designed to provoke
public alarm."111






29Feltner also testied that hospitals do not reach the decision to reprocess lightly.
Rather, they rely on committees made up of physicians, nurses, sterile processing
professionals, infection control specialists, risk managers, and hospital lawyers
to determine whether a specic device can and should be reprocessed. At each
AMDR company, the specic devices are carefully scrutinized in order to deter-
mine whether they can safely and eectively be reprocessed.112
Also, in response to manufacturer complaints that third-party reprocessing is
an \unregulated" industry, Feltner points to the regulations that third-party
reprocessors are required to comply with under FDCA, most signicantly the
Quality System Regulation requirements.113 Under these requirements, repro-
cessors must control and monitor production processes to ensure that a device
conforms to its specications, validate with high degree of assurance that their
reprocessing processes ensure that specied requirements are met, and estab-
lish and maintain procedures for reprocessed device acceptance to ensure that
each production run, lot, or batch meets acceptance criteria.114 In other words,
reprocessors must document that they have developed comprehensive systems
to assure that a reprocessed device is clean, sterile, and able to perform its
originally intended clinical function. According to Feltner, AMDR companies
functionally test every single reprocessed device before sending it back to a hos-




114See 21 CFR Part 820; Food, Drug, and Cosmetic Act (FDCA) x520(f).
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30Feltner concluded that, when performed properly, third-party reprocessing is
safe. Since third-party reprocessors are required to comply with \a host of FDA
requirements," hospitals that take advantage of the benets of third-party re-
processing \can maintain the highest quality patient care, while also achieving
signicant cost savings."116
FDA Regulation of Reuse of Single-Use Devices.
Establishments that engage in manufacturing activities, including the repro-
cessing of single use devices for reuse, may be subject to all requirements of the
Federal Food, Drug, and Cosmetic Act (FDCA), including: registration and
listing,117 premarket notication and approval (PMA) requirements,118 sub-
mission of adverse event reports under the Medical Device Reporting (MDR)
regulation,119 manufacturing requirements under the Quality Systems (QS) reg-
ulation,120 and labeling requirements.121
FDA has recognized generally that user facilities that reprocess medical devices
for reuse are \device manufacturers" within the meaning of the FDCA.122 In
addition, the Medical Device Amendments of 1976123 and the Safe Medical De-
vices Act of 1990124 have provided FDA with broad jurisdiction over device
manufacturing.
Thus far, however, the FDA has not regulated OEMs, third-party reproces-
116Id.
11721 CFR Part 807; FDCA x510.
11821 CFR Parts 807 and 814; FDCA xx510, 513, 515.
11921 CFR Part 803; FDCA x519.
12021 CFR Part 820; FDCA x520(f).
12121 CFR Part 801; FDCA x502.
122See 61 Fed. Reg. 52,602, 52,610 (Oct. 7, 1996).
123Pub. L. No. 94-295, 90 Stat. 539 (1976) (codied at 15 U.S.C. x55).
124Pub. L. No. 101-629, 104 Stat. 4511 (1990) (codied in scattered sections of 21 U.S.C.).
31sors, and health care facilities in the same manner with respect to single-use
devices.125 OEMs have been subject to all the requirements of the FDCA
described above.126 The agency has also described the current regulatory re-
sponsibilities of hospitals that engage in reprocessing in a compliance policy
guide.127 This policy guide has stated that hospitals that reprocess SUDs as-
sume \full liability and responsibility for their reprocessing actions and should
ensure that the products are adequately cleaned and sterilized, and that device
safety, eectiveness, and quality are maintained."128 However, thus far FDA has
exercised its enforcement discretion to, in actual practice, exempt third-party
reprocessors from most premarket and other requirements of the FDCA.
May 1999 FDA and AAMI Conference on Reuse
On May 5-6, 1999, the FDA and the Association for the Advancement of
Medical Instrumentation (AAMI) co-sponsored a conference at Crystal City,
Virginia on the practice of reprocessing and reusing SUDs. Among conference
attendees and participants were representatives of health care facilities, rms
that reprocess devices, OEMs, national oversight organizations, state govern-
ments, academia, medical ethicists, and standards organizations. This provided
the FDA with the opportunity to hear a wide range of views and concerns from
individuals and organizations involved in or aected by the practice of medical
device reuse.
At this meeting, the FDA received divergent opinions on how reprocessing and
125CDRH, \FDA's Proposed Strategy on Reuse of Single-Use Devices," supra note 9.
126Feigal statement, supra note 17.
127FDA, Compliance Policy Guide 300.500 (November 11, 1977).
128Id.
32reuse of SUDs should be regulated. Some participants believed that reprocessors
should be regulated in the same manner as OEMs, and that 510(k)s or Premar-
ket Approval applications (PMAs) demonstrating the safety and eectiveness
of the reprocessed device should be required. Others felt that OEMs should be
required to provide instructions on how to reprocess their devices unless they
can demonstrate that the device cannot be reprocessed.129
Participants of the May 1999 conference also identied the need for additional
guidance on reprocessing. The suggestions posited included: the promulgation
of additional standards to ensure that cleaning, disinfection, and sterilization
processes are validated and that reprocessing may be performed properly; a
determination of what types of devices can and cannot be reprocessed; a clas-
sication scheme establishing critical, semi-critical, and non-critical categories
for reprocessed devices; and clearer denitions for the terms \reuse," \repro-
cessing," and \resterilization."130
November 1999 FDA Proposal131
On November 1, 1999, FDA proposed a more clearly-articulated strategy
that sought to present the various tasks that the FDA, OEMs, third-party re-
processors, health care facilities, professional health care associations and orga-
nizations, the standards development community, and other interested parties
could perform in order to address concerns regarding the practice of reprocess-
ing and reusing single-use products in the United States. This proposal was
129CDRH, \FDA's Proposed Strategy on Reuse of Single-Use Devices," supra note 9.
130Id.
131All the information found in this section may be found in CDRH, \FDA's Proposed
Strategy on Reuse of Single-Use Devices," supra note 9.
33open for a comment period through April of this year, and FDA is currently
attempting to pronounce a nal and binding regulatory proposal. The Novem-
ber proposal contained eight separate sections elucidating diverse tasks that the
agency felt needed to be accomplished. These eight sections will be discussed
briey.
First, FDA proposed to reconsider the agency's current policy on establishments
that reprocess SUDs. According to this statement, if FDA ultimately decides
to regulate health care facilities that reprocess in the same manner as other
reprocessors, such a decision would have a signicant impact on the agency's
resources, particularly for conducting inspections of these facilities. FDA has
indicated that if the agency decided to proceed to regulate health care facili-
ties in the same manner as OEMs, the FDA would consider collaborating with
accredited third-party organizations or other federal agencies to inspect these
facilities to ensure that reprocessing operations were being performed in accor-
dance with FDA's requirements.
Second, FDA sought to explore the development of a device categorization sys-
tem based on the level of risk presented by reprocessing and reusing SUDs.
From this device categorization system, FDA hoped to formulate an enforce-
ment strategy based on the level of risk. Under this risk-based categorization
approach, the agency's application of its authority would depend on the level
of risk associated with the reprocessing and reuse of a particular SUD. FDA
proposed a three-tiered system of device categorization: \low-risk," \moderate-
risk," and \high-risk." Single-use products that are reprocessed because sterility
34was breached by means other than patient contact would also be included in
this risk categorization scheme.
Factors that FDA considered that could determine a SUD's risk category in-
cluded: the complexity of procedures associated with reprocessing the device;
the actual and potential risk for infection should the reprocessed device be
reused; and the quality and extent of published data on reprocessing for the
specic device. \High Risk" Reprocessed SUDs would be products the agency
believes may pose signicant public health risk to patients and users after re-
processing. FDA stated that products in this category should be removed from
the market within a short time frame if they have not complied with applica-
ble premarket requirements. For the \high-risk" category, FDA is considering
enforcing all of the agency's regulatory requirements, including premarket re-
quirements.
In the category of \Low-Risk" Reprocessed SUDs would be included SUDs that
pose \little or no potential public health risk" to patients or users after reprocess-
ing. FDA put forward the expectation that the establishment of inspections for
entities that reprocess \low-risk" SUDs to assure compliance with Good Manu-
facturing Practices (GMP) would be a low priority for the agency. FDA stated
an additional plan to exercise enforcement discretion not to enforce 510(k) sub-
mission requirements, if applicable, for products in this category, provided that
the reprocessors have validated reuse procedures or declare conformity to a rec-
ognized consensus standard that is applicable to the reprocessed SUD. FDA
plans to enforce all other requirements for these products, however, including
35registration and listing requirements.
\Moderate-Risk" Reprocessed SUDs would include those products that are not
in the \low" or \high" risk categories. FDA would enforce applicable premarket
requirements for products in this category to ensure that the reprocessed device
remains as safe and eective as a never-used SUD. FDA stated that it planned
to utilize its enforcement discretion not to enforce premarket requirements for
\moderate-risk" SUDs for a period of two years provided reprocessors collect,
retain, and maintain postmarket data to document the safety, eectiveness, and
performance of reprocessed SUDs in this risk category. But FDA would also
require reprocessors of these moderate-risk devices to comply with registration
and listing, labeling, corrections and removals, quality systems, and tracking.
Finally, with regard to medical device categorization, FDA stated that an SUD's
reuse category under this system might not be a permanent designation. The
categorization system would provide exibility in allowing SUDs to be moved
from one category to another, as more data become available on the risks asso-
ciated with reprocessing and reusing the particular device.
FDA, in its November proposal, also sought to explore how recognized consensus
standards can be applied to reprocessing SUDs (for example, to verify and vali-
date cleaning, disinfection and/or sterilization of SUDs). A further goal of FDA
is the development of additional consensus standards to address the safety, eec-
tiveness, and performance of reprocessed SUDs. One possibility FDA raised was
to allow reprocessors the option to declare conformity to a recognized standard
to ensure that the device remains safe and eective for its intended use. How-
36ever, FDA acknowledges that declarations of conformity to consensus standards
are voluntary. Also, there are a limited number of device-specic performance
standards currently available for SUDs. Therefore, the agency would need to
rely heavily on the cooperation and support of stakeholders and would expect
interested parties to assume primary responsibility for the development of these
standards.
Additional goals mentioned in the FDA November proposal included: examining
the need to create working denitions for the terms \single-use device," \reuse,"
\reprocessing," and \resterilization" such that entities might be aware and in-
formed of their status within the regulatory regime;132 soliciting comments on
the FDA's draft list of \Frequently Reprocessed SUDs";133 and developing a
research program on the reuse of SUDs and exploring avenues to publish and
disseminate research and other information on reuse. Toward this aim, FDA
is considering requesting OEMs to provide information on their labels about
risks associated with reuse of SUDs. Existing statutes and regulations already
require that devices bear adequate directions for use,134 and that the labeling
not be false or misleading.135 The FDA is also considering requesting OEMs
who label their devices \single-use" to provide, as part of the device's labeling,
any information of which they are aware regarding the potential risks associated
with reusing their SUDs.
Finally, FDA announced in its November proposal that it would convene an open
132See Appendix A for the FDA's nal proposed denitions for these terms.
133See Appendix B for the FDA's draft list of frequently reprocessed SUDs.
134FDCA x502(f).
135FDCA x502(a).
37meeting on December 14 to discuss the agency's proposed strategy. Accord-
ingly, on December 14, 1999, the FDA scheduled an open meeting in Rockville,
Maryland to obtain feedback from stakeholders and interested parties on its
proposed strategy on reuse of SUDs. 28 public presenters voiced a variety of
concerns during the rst part of the meeting, and workshops in the afternoon
provided attendees with an opportunity to explore particular issues in smaller
groups.136
February 8, 2000 Draft Guidance Documents
Comments on the November proposal and observations from the December
meeting in Rockville, Maryland have resulted in the most recent step that FDA
has taken toward formulating a regulatory strategy on the reuse of single-use
medical devices. This consists of two draft guidance documents that FDA re-
leased on February 8, 2000, that discuss the agency's prevailing thinking on
the issue. The agency also discussed these documents during the U.S. House
of Representatives subcommittee hearing on February 10. The guidance docu-
ments are not nal, said David W. Feigal, head of FDA's CDRH. But they do
incorporate the latest comments on the agency's proposed strategy.
The new proposed rules would require reprocessors to \prove they can safely
reclean and reuse medical disposable devices | and whether it's safe to reuse
such devices only two or three times, or if ten times is okay."137 In addition,
136Feigal statement, supra note 17.
137\Recycled Medical Devices: FDA Oers More Guidance," American Health Line (Febru-
ary 11, 2000), Politics & Policy Section.
38hospitals and resterilizing companies would have to abide by the same FDA
safety standards as the devices' manufacturers. Reprocessors wanting to recy-
cle high-risk devices, such as angioplasty balloons, which are hard to clean or
sterilize, must seek immediate FDA approval that their methods are \safe and
eective."138 Low-risk devices could be recycled without prior FDA approval,
but must adhere to FDA quality regulations.
The drafts also establish agency priorities for regulating third-party and hospi-
tal reprocessors. One draft, titled \The Reprocessing and Reuse of Single Use
Devices: Review Prioritization Scheme," describes what factors the FDA would
consider in categorizing devices as high-, moderate-, and low-risk.139 It also
lists commonly reprocessed devices, such as orthodontic braces and angioplasty
balloons, and the degree of risk posed by each.140
The second document, \Enforcement Priorities for Single Use Devices Repro-
cessed by Third Parties and Hospitals," details current enforcement priorities
for the FDA. The risk guidance scheme includes two owcharts to help the FDA
and industry categorize the reprocessing risks.141 One chart addresses elements
relating to performance risks of reprocessed devices. The second shows possible
failure risk factors.
FDA intends to begin to enforce premarket notication and premarket appli-
cation requirements within six months of issuance of a nal guidance if the
reprocessed device is categorized as high-risk; within 12 months if moderate;
138Id.
139See Appendices C and D for the owcharts that FDA has created in order to determine
whether a particular medical device should be categorized as high-, moderate-, or low-risk.
140See Appendix B.
141See Appendices C and D.
39and within 18 months for a low-risk device, Feigal said.142 This new FDA pro-
posal was again open for public comment through early April, after which FDA
will attempt to nalize their rule.
During the Congressional hearing in February, Rep. Anna Eshoo (D-Calif.)
questioned the guidance documents' eectiveness, noting, \FDA says all these
devices are subject to regulations, but it won't enforce them unless the device
is considered high-risk."143 She added that reprocessors using recycled devices
deemed moderate- to low-risk will not be required to submit data beforehand.
\We can't put patients at risk to save a few dollars," she said.144
Suggestions and Recommendations for the FDA.
To legislators like Eshoo and others, patient safety is of utmost concern,
but health care cost containment is also of extreme importance. In this age of
rising health care costs, is reprocessing a technology that oers a solution? Dr.
Grossman has posited to FDA and Congress the question: would you want your
loved ones who had the misfortune of being ill to be in the care of a doctor or a
hospital where you not only needed to worry about the disease that has aicted
them, but also had to worry about the safety of the very device used to try to
bring about their wellness?145
FDA has not yet issued a compliance policy guide that addresses third-party
reprocessors of SUDs, although the agency has issued statements in response
142Cheryl A. McMullen, \FDA studies instrument reuse," Waste News (February 21, 2000)
at 3.
143\Recycled Medical Devices: FDA Oers More Guidance," supra note 137.
144Id.
145Grossman statement, supra note 14.
40to specic inquiries. Under current agency policy, third-party reprocessors are
subject to registration, listing, QS, labeling, and MDR reporting requirements.
A recent letter from an agency director has also stated that third-party re-
processors are subject to premarket requirements.146 The FDA however, has
noted that many devices that are commonly reprocessed are exempt, by regula-
tion, from premarket requirements. And over the years, the agency has issued
warning letters to third-party reprocessors for a variety of violations,147 includ-
ing: failure to comply with quality systems requirements, including failure to
validate sterilization procedures; failure to carry labeling statements that a de-
vice has been reprocessed; and failure to bear adequate directions for use.148
While the agency-promulgated regulations may require third-party reprocessors
who engage in certain manufacturing activities to comply with premarket re-
quirements, the FDA, in its enforcement discretion, has as yet not taken action
against third-party reprocessors on the basis of noncompliance with premarket
notication requirements.149
FDA regulation on this issue is currently stagnant. The agency is continually
saying that it needs more clinical data and experience on reuse before it is will-
ing to formulate a clear regulatory stance on SUD reuse; however, the practice
has been occurring for over 20 years now, and FDA still maintains that it does
not possess enough data. Even if the data were insucient, FDA has already
146CDRH, \FDA's Proposed Strategy on Reuse of Single-Use Devices," supra note 9.
147Id. But see also, Feltner statement, supra note 50, noting that many OEM device manu-
facturers themselves also receive warning letters from FDA.
148This regulation is prescribed under 21 U.S.C. 352 (f)(1).
149CDRH, \FDA's Proposed Strategy on Reuse of Single-Use Devices," supra note 9. See
also Feigal statement, supra note 17.
41been mulling over the issue for some three years now.
The agency has called for long-term clinical studies, the establishment of a clear-
inghouse for data, dedication of National Institutes of Health (NIH) funds to
study reprocessing, and research to be conducted by professional societies with
funding provided by OEMs and reprocessors. However, much more needs to
be done. FDA is currently accomplishing little by dragging its feet. Patient
lives may be at stake, and more resources must be devoted to regulation, even
though the limited resources of FDA are immediately apparent.
FDA seems, thus far, to have been characterized by hesitation, indecision, and
uncertainty on this matter. Dr. Feigal's perpetual refrain to the press has been
that \[d]espite a lack of clear data that suggests that many injuries are occur-
ring due to reprocessing practices, FDA has concluded that the practice of reuse
of [SUDs] needs additional attention and controls."150 However, up until now,
FDA has been unwilling or unable to devote the additional attention or controls
that may be necessary for this practice. So far, only 8 companies that repro-
cess disposables for hospitals have registered with the FDA as required by law,
according to agency ocials. Another nine may be registered under dierent
names, and another ve may be in business.151 Also, since 1994, FDA has only
inspected six reprocessing companies | or slightly less than a third of those in
business.152
For many agency ocials, FDA is guilty of \inexcusably belated" action. Ac-
150Cheryl A. McMullen, \FDA studies instrument reuse," Waste News (February 21, 2000)
at 3.
151\FDA exposes patients to risks of medical recycling," USA Today (November 30, 1999)
at 18A.
152Id.
42cording to Larry Kessler, Director of the Oce of Surveillance and Biometrics
at CDRH of the FDA, \The idea of doing something tomorrow doesn't make
any sense... What FDA needs to do is help take the leadership role in creating
a shared vision for what [the practice] should look like in ve and ten years."153
Plainly, FDA's responsibilities stretch its resources. Congress needs to give it
more money and more authority. But, say some, the reuse of disposable devices
\violates both the spirit of the FDA's charter and the faith of consumers."154
The main issues that FDA ought to focus on when trying to formulate a reg-
ulatory scheme are as follows. Should hospitals that recycle and third-party
reprocessors be forced to register with FDA and list the devices they reuse, how
they are cleaned, and what problems result? The answer seems to be clearly
yes; too many issues of concern are at stake, and if hospitals wish to continue
to reprocess in order to cut costs, they ought also to be willing to take on the
additional administrative burden of proving to FDA that such practices are safe
and eective. Should hospitals also inform patients that they will be treated
with reused disposables and oer alternatives, even if alternatives come at a
higher cost? The answer to this question seems less clear, since it appears
that higher-expense alternatives may have the undesirable side eect of making
health care reach prohibitive cost levels for health care consumers. FDA ought
to investigate this question very closely, weighing very carefully and attempt-
ing to balance the competing concerns of patient safety, informed consent, and
hospital and physician discretion.
153Id.
154Id.
43Further, one step which FDA has not yet proposed and which would be bene-
cial to the health care industry as a whole is that OEMs should be required
to submit public documents explaining why a device is labeled as single-use.
Therefore, possible ulterior economic motives for the \single-use" label might
be removed altogether, allowing for an appropriate and proper labeling scheme
that only takes patient safety into account. Device makers, hospitals, and repro-
cessors should also nance FDA-sponsored research to develop quality and man-
ufacturing standards for the riskiest devices, and hospitals and makers should
submit data on adverse events in a way that clearly indicates whether reuse
was a cause. If FDA takes these additional proactive steps in regulating this
growing industry of medical device reuse, a comprehensive regulatory scheme
should emerge, one in which hospitals, patients, original device manufacturers,
and device reprocessors will be able to discern with condence their various
rights and responsibilities.
44Appendix A: FDA Proposed Guidance Denitions155
Single-use device: A single-use device is a device that is intended to be
used only on one
patient during a single procedure. It is not intended to be reprocessed
(cleaned and disinfected/sterilized) and used on another patient. This
labeling identies the device as disposable and does not include
instructions for reprocessing. Some single-use devices are marketed as
non-sterile and include appropriate pre-use sterilization or processing
instructions to make the device patient-ready.
Opened-but-unused: An opened-but unused device is a single-use device
whose sterility has
been breached or whose sterile package was opened but the device has
not been used on a patient.
Reuse: The repeated use or multiple use of any medical device includ-
ing reusable
and single-use medical devices, on the same patient or on dierent
patients, with applicable reprocessing (cleaning and disinfection/
sterilization) between uses.
Reprocessing: Includes all operations performed to render a contaminated
reusable or
single-use device patient-ready. The steps may include cleaning
and
disinfection/sterilization. The manufacturer of reusable devices and
single-use devices that are marketed as non-sterile should provide
validated reprocessing instructions in the labeling.
Resterilization: The repeated application of a terminal process designed
to remove or
destroy all viable forms of microbial life, including bacterial spores,
to an
acceptable sterility level.
155Denitions obtained from CDRH, \Enforcement Priorities for Single-Use Devices Repro-
cessed by Third Parties and Hospitals," at <http://www.fda.gov/cdrh/reuse/1029.html>.
45Appendix B: List of Frequently Reprocessed Single-use
Devices









Cardio- Angiography catheter 870.1200 510(k) high
































Endotracheal Tubes unclassied PMA high











156Chart partially obtained from CDRH, \Reprocessing and Reuse of Single-Use Devices:


















Trocar 876.5090 510(k) low










Laparoscopic Scissors 884.1720 N/A high




Carpal Tunnel Blade 888.4540 N/A moderate











Saw Blades 878.4820 N/A low
Surgical Drills 878.4820 N/A low





Biopsy Needles 878.4800 N/A high







Endoscopes 876.1500 510(k) high




47Endoscopic Staplers 888.4540 N/A moderate




































Laboratory Glucometer Lancets 878.4800 N/A low
Ophthalmic Keratome Blade 886.4370 510(k) high






OR Gowns 878.4040 510(k) low
Sharps Containers 880.5570 510(k) low






Syringe, Irrigating 880.6960 N/A low
Dental Braces, Plastic 872.5470 510(k) high
Braces, Metal 872.5410 N/A high
Burr 872.3240 N/A moderate
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